flecainide has been researched along with Arrhythmogenic Right Ventricular Cardiomyopathy in 7 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is the first reported case of a young woman with a moderate to severe form of arrhythmogenic right ventricular dysplasia under flecainide treatment who, with her physician's consent, decided to have a baby." | 7.70 | Arrhythmogenic right ventricular dysplasia: pregnancy under flecainide treatment. ( Muriago, M; Nava, F; Villanova, C, 1998) |
| "This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC." | 5.72 | Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022) |
| "Recurrence was noted to occur within 2 months of therapy." | 5.46 | Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. ( Ermakov, S; Gerstenfeld, EP; Scheinman, MM; Svetlichnaya, Y, 2017) |
| "This is the first reported case of a young woman with a moderate to severe form of arrhythmogenic right ventricular dysplasia under flecainide treatment who, with her physician's consent, decided to have a baby." | 3.70 | Arrhythmogenic right ventricular dysplasia: pregnancy under flecainide treatment. ( Muriago, M; Nava, F; Villanova, C, 1998) |
| "This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC." | 1.72 | Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022) |
| "Recurrence was noted to occur within 2 months of therapy." | 1.46 | Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. ( Ermakov, S; Gerstenfeld, EP; Scheinman, MM; Svetlichnaya, Y, 2017) |
| "Mutations in pkp2 are detected in arrhythmogenic right ventricular cardiomyopathy (ARVC)." | 1.38 | Sodium current deficit and arrhythmogenesis in a murine model of plakophilin-2 haploinsufficiency. ( Birchmeier, W; Cerrone, M; Chkourko, H; Delmar, M; Hund, T; Liang, FX; Lin, X; Mohler, P; Noorman, M; van der Nagel, R; van Rijen, HV; van Veen, TA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Rolland, T | 1 |
| Badenco, N | 1 |
| Maupain, C | 1 |
| Duthoit, G | 1 |
| Waintraub, X | 1 |
| Laredo, M | 1 |
| Himbert, C | 1 |
| Frank, R | 1 |
| Hidden-Lucet, F | 1 |
| Gandjbakhch, E | 1 |
| Tanaka, TD | 1 |
| Suzuki, T | 1 |
| Marcus, FI | 1 |
| Ermakov, S | 2 |
| Hoffmayer, KS | 1 |
| Gerstenfeld, EP | 2 |
| Scheinman, MM | 2 |
| Svetlichnaya, Y | 1 |
| Calkins, H | 1 |
| Cerrone, M | 1 |
| Noorman, M | 1 |
| Lin, X | 1 |
| Chkourko, H | 1 |
| Liang, FX | 1 |
| van der Nagel, R | 1 |
| Hund, T | 1 |
| Birchmeier, W | 1 |
| Mohler, P | 1 |
| van Veen, TA | 1 |
| van Rijen, HV | 1 |
| Delmar, M | 1 |
| Villanova, C | 1 |
| Muriago, M | 1 |
| Nava, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Randomized Trial With Flecainide in ARVC Patients[NCT03685149] | Phase 2 | 23 participants (Actual) | Interventional | 2019-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for flecainide and Arrhythmogenic Right Ventricular Cardiomyopathy
| Article | Year |
|---|---|
Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy.
Topics: Arrhythmogenic Right Ventricular Dysplasia; Atrial Fibrillation; Defibrillators, Implantable; Flecai | 2022 |
Sustained Wide Complex Tachycardia in a Healthy Man.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Bisoprolol; Defibrillator | 2021 |
Combination drug therapy for patients with intractable ventricular tachycardia associated with right ventricular cardiomyopathy.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Chronic Disease; Dr | 2014 |
Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Catheter Ablation; Combin | 2017 |
Antiarrhythmic drug therapy in patients with arrhythmogenic dysplasia/cardiomyopathy: Is there a role for flecainide?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Arrhythmogenic Right Ventricular Dysplasia; Cardiomyop | 2017 |
Sodium current deficit and arrhythmogenesis in a murine model of plakophilin-2 haploinsufficiency.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Dise | 2012 |
Arrhythmogenic right ventricular dysplasia: pregnancy under flecainide treatment.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Female; Flecainide; Human | 1998 |